Cargando…

Transition to endemic: acceptance of additional COVID-19 vaccine doses among Canadian adults in a national cross-sectional survey

BACKGROUND: Additional doses of COVID-19 vaccine have been proposed as solutions to waning immunity and decreased effectiveness of primary doses against infection with new SARS-CoV-2 variants. However, the effectiveness of additional vaccine doses relies on widespread population acceptance. We aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Reifferscheid, Laura, Lee, Janet Sau Wun, MacDonald, Noni E., Sadarangani, Manish, Assi, Ali, Lemaire-Paquette, Samuel, MacDonald, Shannon E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473459/
https://www.ncbi.nlm.nih.gov/pubmed/36104675
http://dx.doi.org/10.1186/s12889-022-14025-8
_version_ 1784789506526806016
author Reifferscheid, Laura
Lee, Janet Sau Wun
MacDonald, Noni E.
Sadarangani, Manish
Assi, Ali
Lemaire-Paquette, Samuel
MacDonald, Shannon E.
author_facet Reifferscheid, Laura
Lee, Janet Sau Wun
MacDonald, Noni E.
Sadarangani, Manish
Assi, Ali
Lemaire-Paquette, Samuel
MacDonald, Shannon E.
author_sort Reifferscheid, Laura
collection PubMed
description BACKGROUND: Additional doses of COVID-19 vaccine have been proposed as solutions to waning immunity and decreased effectiveness of primary doses against infection with new SARS-CoV-2 variants. However, the effectiveness of additional vaccine doses relies on widespread population acceptance. We aimed to assess the acceptance of additional COVID-19 vaccine doses (third and annual doses) among Canadian adults and determine associated factors. METHODS: We conducted a national, cross-sectional online survey among Canadian adults from October 14 to November 12, 2021. Weighted multinomial logistic regression analyses were used to identify sociodemographic and health-related factors associated with third and annual dose acceptance and indecision, compared to refusal. We also assessed influences on vaccine decision-making, and preferences for future vaccine delivery. RESULTS: Of 6010 respondents, 70% reported they would accept a third dose, while 15.2% were undecided. For annual doses, 64% reported acceptance, while 17.5% were undecided. Factors associated with third dose acceptance and indecision were similar to those associated with annual dose acceptance and indecision. Previous COVID-19 vaccine receipt, no history of COVID-19 disease, intention to receive an influenza vaccine, and increasing age were strongly associated with both acceptance and indecision. Chronic illness was associated with higher odds of acceptance, while self-reported disability was associated with higher odds of being undecided. Higher education attainment and higher income were associated with higher odds of accepting additional doses. Minority first language was associated with being undecided about additional doses, while visible minority identity was associated with being undecided about a third dose and refusing an annual dose. All respondents reported government recommendations were an important influence on their decision-making and identified pharmacy-based delivery and drop-in appointments as desirable. Co-administration of COVID-19 and influenza vaccines was viewed positively by 75.5% of the dose 3 acceptance group, 12.3% of the undecided group, and 8.4% of the refusal group. CONCLUSIONS: To increase acceptance, targeted interventions among visible minority and minority language populations, and those with a disability, are required. Offering vaccination at pharmacies and through drop-in appointments are important to facilitate uptake, while offering COVID-19/influenza vaccine co-administration may have little benefit among those undecided about additional doses. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-14025-8.
format Online
Article
Text
id pubmed-9473459
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94734592022-09-15 Transition to endemic: acceptance of additional COVID-19 vaccine doses among Canadian adults in a national cross-sectional survey Reifferscheid, Laura Lee, Janet Sau Wun MacDonald, Noni E. Sadarangani, Manish Assi, Ali Lemaire-Paquette, Samuel MacDonald, Shannon E. BMC Public Health Research BACKGROUND: Additional doses of COVID-19 vaccine have been proposed as solutions to waning immunity and decreased effectiveness of primary doses against infection with new SARS-CoV-2 variants. However, the effectiveness of additional vaccine doses relies on widespread population acceptance. We aimed to assess the acceptance of additional COVID-19 vaccine doses (third and annual doses) among Canadian adults and determine associated factors. METHODS: We conducted a national, cross-sectional online survey among Canadian adults from October 14 to November 12, 2021. Weighted multinomial logistic regression analyses were used to identify sociodemographic and health-related factors associated with third and annual dose acceptance and indecision, compared to refusal. We also assessed influences on vaccine decision-making, and preferences for future vaccine delivery. RESULTS: Of 6010 respondents, 70% reported they would accept a third dose, while 15.2% were undecided. For annual doses, 64% reported acceptance, while 17.5% were undecided. Factors associated with third dose acceptance and indecision were similar to those associated with annual dose acceptance and indecision. Previous COVID-19 vaccine receipt, no history of COVID-19 disease, intention to receive an influenza vaccine, and increasing age were strongly associated with both acceptance and indecision. Chronic illness was associated with higher odds of acceptance, while self-reported disability was associated with higher odds of being undecided. Higher education attainment and higher income were associated with higher odds of accepting additional doses. Minority first language was associated with being undecided about additional doses, while visible minority identity was associated with being undecided about a third dose and refusing an annual dose. All respondents reported government recommendations were an important influence on their decision-making and identified pharmacy-based delivery and drop-in appointments as desirable. Co-administration of COVID-19 and influenza vaccines was viewed positively by 75.5% of the dose 3 acceptance group, 12.3% of the undecided group, and 8.4% of the refusal group. CONCLUSIONS: To increase acceptance, targeted interventions among visible minority and minority language populations, and those with a disability, are required. Offering vaccination at pharmacies and through drop-in appointments are important to facilitate uptake, while offering COVID-19/influenza vaccine co-administration may have little benefit among those undecided about additional doses. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12889-022-14025-8. BioMed Central 2022-09-14 /pmc/articles/PMC9473459/ /pubmed/36104675 http://dx.doi.org/10.1186/s12889-022-14025-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Reifferscheid, Laura
Lee, Janet Sau Wun
MacDonald, Noni E.
Sadarangani, Manish
Assi, Ali
Lemaire-Paquette, Samuel
MacDonald, Shannon E.
Transition to endemic: acceptance of additional COVID-19 vaccine doses among Canadian adults in a national cross-sectional survey
title Transition to endemic: acceptance of additional COVID-19 vaccine doses among Canadian adults in a national cross-sectional survey
title_full Transition to endemic: acceptance of additional COVID-19 vaccine doses among Canadian adults in a national cross-sectional survey
title_fullStr Transition to endemic: acceptance of additional COVID-19 vaccine doses among Canadian adults in a national cross-sectional survey
title_full_unstemmed Transition to endemic: acceptance of additional COVID-19 vaccine doses among Canadian adults in a national cross-sectional survey
title_short Transition to endemic: acceptance of additional COVID-19 vaccine doses among Canadian adults in a national cross-sectional survey
title_sort transition to endemic: acceptance of additional covid-19 vaccine doses among canadian adults in a national cross-sectional survey
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9473459/
https://www.ncbi.nlm.nih.gov/pubmed/36104675
http://dx.doi.org/10.1186/s12889-022-14025-8
work_keys_str_mv AT reifferscheidlaura transitiontoendemicacceptanceofadditionalcovid19vaccinedosesamongcanadianadultsinanationalcrosssectionalsurvey
AT leejanetsauwun transitiontoendemicacceptanceofadditionalcovid19vaccinedosesamongcanadianadultsinanationalcrosssectionalsurvey
AT macdonaldnonie transitiontoendemicacceptanceofadditionalcovid19vaccinedosesamongcanadianadultsinanationalcrosssectionalsurvey
AT sadaranganimanish transitiontoendemicacceptanceofadditionalcovid19vaccinedosesamongcanadianadultsinanationalcrosssectionalsurvey
AT assiali transitiontoendemicacceptanceofadditionalcovid19vaccinedosesamongcanadianadultsinanationalcrosssectionalsurvey
AT lemairepaquettesamuel transitiontoendemicacceptanceofadditionalcovid19vaccinedosesamongcanadianadultsinanationalcrosssectionalsurvey
AT macdonaldshannone transitiontoendemicacceptanceofadditionalcovid19vaccinedosesamongcanadianadultsinanationalcrosssectionalsurvey